This inventor holds 2 USPTO granted patents and 3 EPO patents. Top assignees: Xiamen University, Yang Sheng Tang Company Limited. Active years: 2013-2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Xiamen, CN (2013)
- Fujian, CN (2017)
Company Filing History:
2 out of 165 
1 out of 13 Years Active: 2013-2017
Title: Innovations of Honglin Chen in Influenza Virus Research
Introduction
Honglin Chen is a prominent inventor based in Xiamen, China. He has made significant contributions to the field of virology, particularly in the development of monoclonal antibodies for the prevention and treatment of influenza viruses. With a total of 2 patents, his work has the potential to impact public health significantly.
Latest Patents
Honglin Chen's latest patents include groundbreaking inventions related to monoclonal antibodies. The first patent focuses on a broad-spectrum monoclonal antibody that recognizes the HA1 domain of hemagglutinin of the influenza virus. This invention relates to antibodies that can specifically bind to the HA1 domain of different HA subtypes, including H1 and H5 subtypes. The antibodies can be utilized in vaccines or pharmaceutical compositions aimed at preventing and treating infections caused by these influenza virus subtypes.
The second patent provides monoclonal antibodies that specifically bind to H5 subtype avian influenza virus hemagglutinin. These antibodies can block the binding activity of at least 50% of known monoclonal antibodies to the H5 subtype. This invention also includes hybridoma cell lines, isolated nucleic acid molecules, and medical compositions for the detection, diagnosis, prevention, and treatment of avian influenza viruses.
Career Highlights
Honglin Chen has worked with notable institutions, including Xiamen University and Yang Sheng Tang Company Limited. His research has been pivotal in advancing the understanding and treatment of influenza viruses.
Collaborations
He has collaborated with colleagues such as Yixin Chen and Wenxin Luo, contributing to the collective knowledge and innovation in the field of virology.
Conclusion
Honglin Chen's innovative work in developing monoclonal antibodies for influenza viruses showcases his dedication to improving public health. His patents represent significant advancements in the fight against viral infections, particularly in the context of avian influenza and seasonal flu.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile